Ainos Inc (AIMD): $AIMD -Ainos | BREAKINGNEWS! Ainos Unvei...

$AIMD -Ainos / BREAKINGNEWS! Ainos Unveils Critical Progress

QuicKtip · 2024-06-14T14:04:07.2070000Z

$AIMD -Ainos | BREAKINGNEWS! Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA https://www.accesswire.com/877292/ainos-unveils-critical-progress-in-ainos-flora-clinical-trials-and-next-gen-plans-powered-by-nvidia-cuda

Play Episode

7min

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

Cordiant Digital Infrastructure Management chair on capital strategy & growth focus

Cordiant Digital Infrastructure Ltd (LSE:CORD) Chairman Steven Marshall talked with Proactive's Stephen Gunnion about the company’s capital allocation strategy and growth outlook, particularly in the context of rising interest rates and macroeconomic pressures. Marshall highlighted how Cordiant Digital has strategically invested in cash-generative assets within two of Europe’s fastest-growing economies—Poland and the Czech Republic. “We can actually buy small bolt-on businesses, we can invest in organic growth, which actually is at a much lower cost than actually the buyback rates that we're getting,” Marshall said. The company has balanced yield and reinvestment, maintaining a dividend yield just under 5%, which is currently covered 1.8 times by free cash flow. Marshall explained the business has focused on acquiring quality mid-market assets with strong management teams and brand value. Looking ahead, Cordiant Digital aims to continue growing its portfolio through bolt-on acquisitions and organic investments, such as expanding distributed antenna broadband networks in Prague and Warsaw, and further developing data centre and mobile tower infrastructure in Poland. Marshall indicated the company is unlikely to pursue additional share buybacks in the short term, preferring to direct capital towards growth opportunities offering better long-term returns. Visit Proactive's YouTube channel for more interviews and insights. Don't forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #CordiantDigital #InfrastructureInvestment #DigitalGrowth #DividendStocks #EmergingMarkets #PolandInvestment #CzechRepublic #CapitalAllocation #TelecomInfrastructure #DataCenters #InvestorUpdate

Proactive - Interviews for investors

MP Evans posts record 2024 results, eyes growth

MP Evans Group PLC (AIM:MPE) CEO Matthew Coulson takes Proactive's Stephen Gunnion through the company’s record results for 2024 and the strong start to 2025. MP Evans Group reported a robust financial performance in 2024, with Coulson confirming a record profit and a 66% increase in earnings per share. “It’s been a fantastic year for the group,” Coulson said, noting that high pricing supported the result, with prices averaging around $820 per tonne for the year. The company processed 1.6 million tonnes of crop in 2024, maintaining output despite weather-related challenges in Indonesia. Coulson highlighted this achievement in context: while Indonesia saw a slight national decline in crop yield, MP Evans sustained high volumes, reflecting operational resilience. Planting activity also continued across its operations, particularly in South Sumatra and East Kalimantan. The company expects to exceed 11,000 hectares planted at its Musi Rawas estate in early 2025, while its ABK site in East Kalimantan is set for more extensive development this year. Coulson also noted a milestone in sustainability, with over 250,000 tonnes of certified sustainable output processed across the company’s six mills in 2024. Looking ahead, he said 2025 had started positively, with pricing in the first two months averaging $870 per tonne, and the company is actively exploring acquisition opportunities. Visit Proactive’s YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #MPEvans #PalmOil #Agribusiness #SustainableFarming #IndonesiaAgriculture #CropProduction #AgricultureInvestment #ESGInvesting #DividendStocks #CommoditiesMarket #ProactiveInvestors

Followers	17
Posts	4747
Boards Moderated	0
Alias Born	08/23/2022

Volume:	20
Day Range:
Bid:	0.46
Ask:	0.50
Last Trade Time:	5:05:45 AM EDT
Total Trades:	1

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AIMD Detailed Quote

Recent AIMD News

More AIMD News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent AIMD News

Go Ad-Free